Royal Sense (ROYAL) | Financial Analysis & Statements
Royal Sense Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Sep 2023Income Metrics
Revenue
33.9M
Gross Profit
5.3M
15.60%
Operating Income
2.6M
7.66%
Net Income
2.0M
5.79%
Balance Sheet Metrics
Total Assets
240.3M
Total Liabilities
34.4M
Shareholders Equity
205.9M
Debt to Equity
0.17
Cash Flow Metrics
Operating Cash Flow
50.9M
Free Cash Flow
26.6M
Revenue & Profitability Trend
Quarter Income Flow
Sep 30, 2023
Annual Income Flow
2025
Royal Sense Income Statement From 2022 to 2025
| Metric | 2025 | 2024 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | 617.3M | 220.2M | 178.0M | 0 | 67.5M |
| Cost of Goods Sold | 495.7M | 182.4M | 146.3M | 0 | 61.5M |
| Gross Profit | 121.6M | 37.8M | 31.7M | 0 | 6.0M |
| Gross Margin % | 19.7% | 17.2% | 17.8% | 0.0% | 8.8% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 9.6M | - | 1.6M | 1.5M | 99.0K |
| Other Operating Expenses | 5.0M | 3.3M | 1.2M | 532.0K | 2.2M |
| Total Operating Expenses | 14.6M | 3.3M | 2.8M | 2.0M | 2.3M |
| Operating Income | 88.7M | 31.8M | 23.1M | 0 | 2.2M |
| Operating Margin % | 14.4% | 14.4% | 13.0% | 0.0% | 3.2% |
| Non-Operating Items | |||||
| Interest Income | 787.0K | - | 304.0K | 4.0K | 25.0K |
| Interest Expense | 1.4M | 381.0K | 626.0K | 0 | 0 |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 87.3M | 31.8M | 22.0M | 0 | 2.2M |
| Income Tax | 24.0M | 8.0M | 6.1M | 0 | 0 |
| Effective Tax Rate % | 27.5% | 25.2% | 27.7% | 0.0% | 0.0% |
| Net Income | 63.3M | 23.8M | 15.9M | 0 | 2.2M |
| Net Margin % | 10.3% | 10.8% | 8.9% | 0.0% | 3.2% |
| Key Metrics | |||||
| EBITDA | 89.0M | 32.2M | 22.7M | 0 | 2.3M |
| EPS (Basic) | - | ₹4.85 | ₹3.24 | ₹0.00 | ₹0.45 |
| EPS (Diluted) | - | ₹4.85 | ₹3.24 | ₹0.00 | ₹0.45 |
| Basic Shares Outstanding | - | 4898969 | 4900146 | 4900146 | 4900146 |
| Diluted Shares Outstanding | - | 4898969 | 4900146 | 4900146 | 4900146 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Royal Sense Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 112.5M | 87.4M | 16.2M | 259.0K | 1.1M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 145.6M | 32.2M | 51.4M | 12.9M | 5.0M |
| Inventory | 57.5M | 41.5M | 4.0M | 409.0K | 1.7M |
| Other Current Assets | 753.0K | 267.0K | - | 2.0K | -1.0K |
| Total Current Assets | 333.5M | 201.8M | 73.2M | 15.6M | 10.5M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 0 | 0 | - | - | - |
| Goodwill | 215.0K | 52.0K | 6.0K | 7.0K | 10.0K |
| Intangible Assets | 215.0K | 52.0K | 6.0K | 7.0K | 10.0K |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | -1.0K | 11.0K | - | -1.0K | -1.0K |
| Total Non-Current Assets | 22.1M | 5.9M | 545.0K | 406.0K | 1.7M |
| Total Assets | 355.6M | 207.7M | 73.7M | 16.0M | 12.2M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 12.5M | 262.0K | 34.0M | 6.2M | 6.6M |
| Short-term Debt | 31.5M | 13.8M | 5.2M | 3.2M | 0 |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 8.8M | 1.0K | - | - | 1.0K |
| Total Current Liabilities | 76.3M | 23.3M | 40.6M | 9.5M | 7.4M |
| Non-Current Liabilities | |||||
| Long-term Debt | 1.0M | 2.2M | - | - | - |
| Deferred Tax Liabilities | 30.0K | 3.0K | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1.0K | -1.0K | 1.0K | - | - |
| Total Non-Current Liabilities | 1.9M | 2.2M | 1.0K | 0 | 0 |
| Total Liabilities | 78.3M | 25.5M | 40.6M | 9.5M | 7.4M |
| Equity | |||||
| Common Stock | 49.7M | 49.0M | 33.1M | 6.5M | 4.8M |
| Retained Earnings | 79.2M | 15.9M | 0 | 0 | 0 |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 277.4M | 182.2M | 33.1M | 6.5M | 4.8M |
| Key Metrics | |||||
| Total Debt | 32.6M | 16.0M | 5.2M | 3.2M | 0 |
| Working Capital | 257.2M | 178.5M | 32.6M | 6.1M | 3.1M |
Balance Sheet Composition
Royal Sense Cash Flow Statement From 2022 to 2025
| Metric | 2025 | 2024 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 87.3M | 31.8M | 22.0M | 13.2M | 2.2M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | -83.5M | -81.2M | -40.7M | -37.5M | -3.6M |
| Operating Cash Flow | 5.2M | -49.4M | -18.4M | -24.0M | -1.4M |
| Investing Activities | |||||
| Capital Expenditures | -16.2M | -161.0K | -335.0K | 0 | 0 |
| Acquisitions | 0 | 0 | 249.0K | 0 | - |
| Investment Purchases | -50.0K | -10.8M | -4.0M | -193.0K | - |
| Investment Sales | - | - | - | - | 795.0K |
| Investing Cash Flow | -16.4M | -10.9M | -5.2M | -193.0K | 1.3M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | -1.2M | - | 0 | - | - |
| Financing Cash Flow | 30.8M | 0 | 155.5M | 13.4M | -486.0K |
| Free Cash Flow | -4.1M | -45.8M | -39.1M | 0 | -1.6M |
| Net Change in Cash | 19.6M | -60.3M | 131.9M | -10.7M | -612.0K |
Cash Flow Trend
Royal Sense Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
14.61
Price to Book
2.60
Price to Sales
1.11
Profitability Ratios
Profit Margin
9.63%
Operating Margin
13.28%
Return on Equity
28.62%
Return on Assets
18.97%
Financial Health
Current Ratio
3.16
Debt to Equity
19.41
Beta
0.59
Per Share Data
EPS (TTM)
₹11.83
Book Value per Share
₹66.58
Revenue per Share
₹160.73
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ROYAL | 924.5M | 14.61 | 2.60 | 28.62% | 9.63% | 19.41 |
| Entero Healthcare | 54.7B | 48.93 | 3.11 | 5.36% | 1.87% | 24.63 |
| NOVELIX | 1.2B | 48.76 | 3.10 | 0.48% | 1.41% | 0.00 |
| Amwill Health Care | 669.9M | 8.73 | 0.96 | 15.50% | 20.93% | 0.00 |
| Trimurthi | 500.4M | 102.35 | - | 0.00% | 3.73% | - |
| Welcure Drugs | 370.8M | 1.30 | 0.28 | 2.12% | 12.21% | 91.72 |
Financial data is updated regularly. All figures are in the company's reporting currency.



